Biomarker conservation in primary and metastatic epithelial ovarian cancer

被引:45
|
作者
Tewari, KS
Kyshtoobayeva, AS
Mehta, RS
Yu, IR
Burger, RA
DiSaia, PJ
Fruehauf, JP
机构
[1] Oncotech Inc, Irvine, CA 92614 USA
[2] Univ Calif Irvine, Irvine Med Ctr, Chao Family Comprehens Canc Ctr, Div Gynecol Oncol,Sect Hematol & Oncol, Orange, CA 92868 USA
关键词
ovarian cancer; biomarkers; biologic prognostic factors; clonal divergence; angiogenesis; tumor heterogeneity;
D O I
10.1006/gyno.2000.5837
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose. The aim of this study was to compare the overexpression of specific biomarkers in primary advanced and recurrent epithelial ovarian cancers. Methods. Biomarker expression by epithelial ovarian cancer specimens from primary and metastatic sites was examined by immunohistochemistry and flow cytometry. Biomarker expression by subpopulations of tissues consisting of matched pairs of synchronous and metachronous lesions was also studied. Results. A total of 3173 epithelial ovarian cancer specimens were retrieved from women with FIGO Stage III/IV disease. These included lesions from 1036 primary and 2137 metastatic sites. The percentages of biomarker expression for primary and metastatic lesions, respectively, were MDR1, 12 and 10%; p53, 55 and 60%; HER2, 12 and 11%; EGF-R, 26 and 33%; increased microvessel counts (CD31), 21 and 36%. Approximately 73% of both primary and metastatic specimens were aneuploid, and approximately 57% of both sets had an S-phase fraction >7%. Only EGF-R and CD31 expression were found to be significantly different between the primary and metastatic tumors (P < 0.05). Of the paired synchronous cases (n = 48) evaluated, 88% of aneuploid primary lesions were associated with aneuploid metastases. Similarly, the distributions for MDR1, HER2, and p53 expression did not vary significantly between primary and metastatic sites. Pairings of metachronous cases (n = 66) revealed that nearly 80% of primary aneuploid tumors (n = 39) retained their aneuploid status at the time of relapse. Furthermore, there were no significant changes in MDR1, p53, or HER2 expression at relapse. Conclusions. With the exception of EGFR and CD31, clonal divergence of the biomarkers evaluated in this study probably does not play a significant role in imparting clinical heterogeneity during the advanced and recurrent stages of epithelial ovarian cancer. These particular genes likely undergo alterations early in the tumorigenesis process before metastases have become established, (C) 2000 Academic Press.
引用
收藏
页码:130 / 136
页数:7
相关论文
共 50 条
  • [21] Evaluation of Glycomic Profiling as a Diagnostic Biomarker for Epithelial Ovarian Cancer
    Kim, Kyoungmi
    Ruhaak, L. Renee
    Uyen Thao Nguyen
    Taylor, Sandra L.
    Dimapasoc, Lauren
    Williams, Cynthia
    Stroble, Carol
    Ozcan, Sureyya
    Miyamoto, Suzanne
    Lebrilla, Carlito B.
    Leiserowitz, Gary S.
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2014, 23 (04) : 611 - 621
  • [22] Lipocalin 2 as a diagnostic and prognostic biomarker for epithelial ovarian cancer
    Cho, H.
    Hong, S.
    Kim, S.
    Kim, S.
    Kim, J.
    Kim, Y.
    GYNECOLOGIC ONCOLOGY, 2009, 112 (02) : S140 - S140
  • [23] Identification of two theranostic biomarker panels for epithelial ovarian cancer
    Habel, Azza
    Xu, Weili
    Ahmed, Mariem Hadj
    Stayoussef, Mouna
    Bouaziz, Hanen
    Ayadi, Mouna
    Mezlini, Amel
    Larbi, Anis
    Yaacoubi-Loueslati, Basma
    CYTOKINE, 2023, 161
  • [24] Progress in biomarker discovery for diagnostic testing in epithelial ovarian cancer
    Gogoi, Radhika
    Srinivasan, Shankar
    Fishman, David A.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2006, 6 (04) : 627 - 637
  • [25] PROSAPOSIN, A NOVEL BIOMARKER FOR PRIMARY AND METASTATIC PROSTATE CANCER
    Koochekpour, Shahriar
    Hu, SiYi
    Velasco-Gonzalez, Cruz
    El Badri, Mohamed
    Bernardo, Ruiz
    Zieske, Arthur
    Azabdaftari, Gissou
    Chung, Leland
    Zhau, Haiyen
    Vessella, Robert
    Garai, Jone
    JOURNAL OF UROLOGY, 2011, 185 (04): : E935 - E936
  • [26] Genomic analyses of primary and metastatic serous epithelial ovarian cancer (vol 154, pg 16, 2004)
    Israeli, Ofir
    Gotlieb, Walter H.
    Friedman, Eitan
    Korach, Jacob
    Friedman, Eddy
    Goldman, Boleslaw
    Zeltzer, Assaf
    Ben-Baruch, Gilad
    Rienstein, Shlomit
    Aviram-Goldring, Ayala
    CANCER GENETICS, 2011, 204 (08) : 476 - 476
  • [27] Expression of MUC1 in primary and metastatic human epithelial ovarian cancer and its therapeutic significance
    Wang, Li
    Ma, Jie
    Liu, FengHua
    Yu, QingKai
    Chu, GuangMin
    Perkins, Alan C.
    Li, Yong
    GYNECOLOGIC ONCOLOGY, 2007, 105 (03) : 695 - 702
  • [28] PDE1A in epithelial ovarian cancer: Oncogenic role, metastatic association, and potential as a prognostic biomarker and therapeutic target
    Han, Gwan Hee
    Yun, Hee
    Cho, Hanbyoul
    Chung, Joon-Yong
    Kim, Jae-Hoon
    GYNECOLOGIC ONCOLOGY, 2024, 190 : S186 - S186
  • [29] Biomarker comparison of epithelial ovarian cancer and endometrial cancer by multiplatform tumor profiling
    Mahdi, H.
    Xiu, J.
    Reddy, S. K.
    DeBernardo, R.
    GYNECOLOGIC ONCOLOGY, 2015, 137 : 208 - 208
  • [30] THE APPENDIX AND ITS METASTATIC POTENTIAL IN EPITHELIAL OVARIAN-CANCER
    MALFETANO, JH
    OBSTETRICS AND GYNECOLOGY, 1987, 69 (03): : 396 - 398